Clinical Trials Browser

Phase 1/2 × Terminated × Clofarabine × Clear all

Leukemia, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT00691652 2019-11-27

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

Burkitt Lymphoma, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT01160354 2019-08-28

Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)

Phase 1/2 Terminated

22 enrolled 9 charts

Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT00708721 2017-06-01

Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Phase 1/2 Terminated

11 enrolled 11 charts

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myelomonocytic, Chronic

Clinical Trials

Alemtuzumab and Clofarabine for Relapsed or Refractory Acute Lymphoblastic Leukemia

Clofarabine and Rituximab in Treating Patients With Relapsed Non-Hodgkin Lymphoma

Plerixafor and Clofarabine in Frontline Treatment of Elderly Patients With Acute Myelogenous Leukemia (AML)

Low-dose Oral Clofarabine for the Treatment of IPSS INT-1, INT-2 or HIGH Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia